Outcome of liver cancer patients with SARS-CoV-2 infection.

Muñoz-Martínez, Sergio; Sapena, Victor; Forner, Alejandro; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Ríos, José; Bouattour, Mohamed; El Kassas, Mohamed; Leal, Cassia Regina Guedes; Mocan, Tudor; Nault, Jean-Charles; Alves, Rogerio Camargo Pinheiro; Reeves, Helen L; da Fonseca, Leonardo; García-Juárez, Ignacio; Pinato, David J; Varela, María; Alqahtani, Saleh A; Alvares-da-Silva, Mario Reis; Bandi, Juan C; ... (2022). Outcome of liver cancer patients with SARS-CoV-2 infection. Liver international, 42(8), pp. 1891-1901. Wiley 10.1111/liv.15320

[img] Text
Liver_International_-_2022_-_Mu_oz_Mart_nez_-_Outcome_of_liver_cancer_patients_with_SARS_CoV_2_infection.pdf - Accepted Version
Restricted to registered users only until 25 May 2023.
Available under License Publisher holds Copyright.

Download (432kB) | Request a copy

BACKGROUND & AIMS

Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.

METHODS

Multicenter retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February-December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.

RESULTS

Two-hundred-fifty patients from 38 centers were included, 218 with hepatocellular carcinoma (HCC), 32 with intrahepatic cholangiocarcinoma (iCCA). Median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts, respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 [IQR:1.84-11.24] months, 100 (40%) patients have died,48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage [6.10%(95%CI 2.24-12.74), 11.76%(95%CI 4.73-22.30), 20.69%(95%CI 11.35-31.96), and 34.52%(95%CI 17.03-52.78) for BCLC 0/A, B, C and D respectively; p=0.0017]. The Hazard Ratio was 1.45 (95%CI 0.49-4.31; p=0.5032) in BCLC-B vs 0/A, and 3.13 (95%CI 1.29-7.62; p=0.0118) in BCLC-C vs 0/A in the Competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, 12 deaths related to SARS-CoV-2 infection.

CONCLUSIONS

This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery

UniBE Contributor:

Lachenmayer, Anja

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1478-3231

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

25 May 2022 12:08

Last Modified:

23 Jul 2022 00:14

Publisher DOI:

10.1111/liv.15320

PubMed ID:

35608939

Uncontrolled Keywords:

COVID-19 Hepatocellular carcinoma Liver cancer mortality

BORIS DOI:

10.48350/170248

URI:

https://boris.unibe.ch/id/eprint/170248

Actions (login required)

Edit item Edit item
Provide Feedback